相关实验视频
Updated: Jun 23, 2025

05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
548
随机测定的β-胡卜素补充剂对男性CKD的影响
Api Chewcharat1, Pol Chewcharat2, Kathryn M Rexrode3
1Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Kidney international reports
|June 20, 2024
概括
补充β-胡卜素 (BC) 并没有降低中年和老年男性医生慢性病 (CKD) 的风险. 这项长期随机试验发现,与安慰剂相比,BC组对脏健康没有显著的益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 营养科学 营养科学
- 流行病学 流行病学
背景情况:
- β-胡卜素 (BC) 是一种抗氧化剂,具有对损伤的潜在保护作用.
- 动物研究表明,BC补充剂可以减轻损伤并改善功能.
- 人类对BC对病,特别是慢性病 (CKD) 的影响的数据有限.
研究的目的:
- 研究β-胡卜素补充剂对发生慢性病 (CKD) 的长期影响.
- 分析BC对中年和老年男性医生的CKD风险的影响.
- 探索吸烟状态是否会改变BC补充剂和CKD之间的关联.
主要方法:
- 利用了来自医生健康研究I的数据,这是一项随机试验,涉及10,966名接受BC和10,952名接受安慰剂的参与者.
- 事件CKD是通过自我报告识别的,并通过估计的膜过率 (eGFR) <60毫升/分钟/1.73米2来定义.
- 考克斯的比例危险和逻辑回归模型被用来比较群体之间的CKD发病率,调整共变量并按吸烟状况分层.
主要成果:
- 在BC和安慰剂组之间没有观察到自我报告的发生性CKD的显著差异 (HR=0.97,P=0.56).
- 在目前的吸烟者或前/从未吸烟者中,BC补充对CKD风险没有显著的益处.
- 基于eGFR<60毫升/分钟/1.73米2的亚组分析也显示,BC补充没有显著的益处 (OR=0.96,P=0.49).
结论:
- 长期随机服用β-胡卜素补充剂 (50毫克每隔一天) 并没有降低中年和老年男性医生中发生CKD的风险.
- 吸烟状态没有改变BC补充剂和CKD风险之间的关系.
- 这些发现不支持在这个人群中使用β-胡卜素作为CKD的初级预防.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
81
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
81
Renal Failure: Dose Adjustments
80
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
80
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420

